Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters










Publication year range
5.
J Forensic Sci ; 24(1): 76-86, 1979 Jan.
Article in English | MEDLINE | ID: mdl-512618

ABSTRACT

Potential predictors of outcome following acute glutethimide overdosage were assessed in 63 patients hospitalized with this diagnosis at a large urban medical center between 1962 and 1975. Their mean age was 34 years (range, 15 to 84 years) and 62% were female. Assisted ventilation was required in 59% of cases, and 32% developed hypotension. Six patients died, including all three aged 60 years or older. Multiple regression analysis confirmed that age was the major identifiable determinant of survival, regardless of other factors. Among identifiable determinants of coma grade, glutethimide dose, glutethimide plasma concentration, and coingestion of barbiturates were the most important. An ingested dose of 10 g or more, or a plasma concentration exceeding 30 microgram/ml, was almost always associated with deep coma. However, a relatively small ingested dose or a low plasma level by no means ruled out development of serious intoxication, particularly in those patients who also ingested barbiturates. Thus elderly individuals are at high risk for fatal outcome following glutethimide overdosage and should receive priority for intensive care and monitoring. Glutethimide dose, plasma concentration, and history of coingestion of barbiturates are of value in predicting development of deep coma. These items of information should be obtained on admission whenever possible.


Subject(s)
Glutethimide/poisoning , Adolescent , Adult , Age Factors , Aged , Barbiturates/administration & dosage , Diagnosis , Female , Glutethimide/administration & dosage , Glutethimide/blood , Humans , Male , Middle Aged , Regression Analysis
7.
Am J Cardiol ; 35(1): 67-71, 1975 Jan.
Article in English | MEDLINE | ID: mdl-1109248

ABSTRACT

The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. Each subject received an individualized fixed daily dose of warfarin and served as his own pre- and postsedative treatment control. Prothrombin times were measured four times weekly during five long-term experiments. Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone. Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. The concurrent use of drugs from these groups is decreasing according to a survey of 200 hospital medical records. Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.


Subject(s)
Blood Coagulation/drug effects , Chloral Hydrate/adverse effects , Drug Interactions , Glutethimide/adverse effects , Methaqualone/adverse effects , Phenobarbital/adverse effects , Secobarbital/adverse effects , Warfarin/therapeutic use , Administration, Oral , Adult , Aged , Chloral Hydrate/administration & dosage , Glutethimide/administration & dosage , Humans , Male , Methaqualone/administration & dosage , Middle Aged , Phenobarbital/administration & dosage , Prothrombin Time , Secobarbital/administration & dosage , Warfarin/administration & dosage , Warfarin/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...